Beta Bionics, Inc. (NASDAQ:BBNX) Sees Large Decline in Short Interest

Posted by Brian Himes on Oct 15th, 2026

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 6,046,389 shares, a drop of 43.1% from the September 15th total of 10,617,768 shares. Approximately 14.2% of the shares of the company are short sold. Based on an average trading volume of 1,859,712 shares, the short-interest ratio is currently 3.3 days.

Insiders Place Their Bets

In other Beta Bionics news, insider Mike Mensinger sold 2,650 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the sale, the insider directly owned 177,390 shares of the company’s stock, valued at $3,902,580. This represents a 1.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 30,779 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27. Following the completion of the sale, the insider directly owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. This trade represents a 35.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock valued at $1,907,034 in the last 90 days. 5.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Beta Bionics

Hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its holdings in Beta Bionics by 1,075.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the last quarter. Legal & General Group Plc acquired a new position in Beta Bionics in the second quarter valued at about $62,000. The Manufacturers Life Insurance Company bought a new stake in Beta Bionics during the second quarter worth about $172,000. Ieq Capital LLC bought a new stake in Beta Bionics during the second quarter worth about $229,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Beta Bionics during the second quarter worth approximately $264,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

Negative Sentiment: The lawsuit alleges that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints, including reports allegedly involving severe or life-threatening hypoglycemia. These claims have not been proven. SueWallSt Beta Bionics lawsuit notice
Negative Sentiment: Investors are also alleging that company filings understated or omitted the significance of FDA concerns, including a June 2025 Form 483 and subsequent scrutiny of the iLet system’s quality controls and complaint reporting. Levi and Korsinsky Beta Bionics notice
Negative Sentiment: The legal notices state that surprise revelations about FDA concerns contributed to sharp earlier declines in BBNX shares, with one firm citing a 37% drop and another alleging the stock had lost as much as 72% during the relevant period. The litigation creates potential legal costs, reputational damage and additional uncertainty regarding the company’s product and controls. Beta Bionics investor deadline notice
Neutral Sentiment: Multiple firms, including Schall Brown & Schwartz, Pomerantz, Rosen, Kaplan Fox and others, are soliciting investors who purchased BBNX shares from July 30, 2025, through February 24, 2026, to seek lead-plaintiff status. The deadline is November 3, 2026; these announcements repeat the same pending case rather than reporting a new company operating update. Schall Brown and Schwartz Beta Bionics alert

Beta Bionics Trading Up 2.1%

BBNX stock traded up $0.35 during trading on Thursday, hitting $17.22. The company had a trading volume of 462,037 shares, compared to its average volume of 1,174,255. The company has a fifty day moving average price of $18.97 and a two-hundred day moving average price of $15.14. The company has a market cap of $774.73 million, a P/E ratio of -10.43 and a beta of 3.39. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. On average, analysts expect that Beta Bionics will post -2.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Beta Bionics from a “sell” rating to a “hold” rating in a research note on Saturday, September 19th. Truist Financial upped their price target on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, September 24th. Jefferies Financial Group began coverage on Beta Bionics in a research report on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Barclays assumed coverage on Beta Bionics in a research report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Robert W. Baird lifted their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Read Our Latest Stock Report on Beta Bionics

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.